Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935259 | 0.98 | MCL1 (0.49) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL4751506 | 0.96 | MCL1 (0.46) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL14484973 | 0.86 | MCL1 (0.46) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL18796201 | 0.82 | MCL1 (0.49) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL28595966 | 0.80 | MCL1 (0.40) | MCL1MAPK1CYP1A2RECQL | |
| SCHEMBL1903199 | 0.78 | MCL1 (0.32) | MCL1 | |
| SCHEMBL1008181 | 0.77 | MCL1 (0.45) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL15893192 | 0.77 | MCL1 (0.52) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL10458616 | 0.76 | MCL1 (0.55) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL16534456 | 0.76 | MCL1 (0.55) | MCL1MAPK1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-109928983-B | 2-oxadiazole-3-aminothieno [2,3-b ] pyridine derivative and preparation method and application thereof | 四川大学 | 2021-06-29 | — | — | CN | disclosed |
| CN-106928250-B | 2-oxadiazole-3-aminothieno [2,3-b ] pyridine derivative and preparation method and application thereof | 四川大学 | 2019-09-27 | — | — | CN | disclosed |
| CN-109928983-A | 2- oxadiazoles -3- aminothiophene simultaneously [2,3-b] pyridine derivate and its preparation method and application | 四川大学 | 2019-06-25 | — | — | CN | disclosed |
| CN-106928250-A | 2-oxadiazole-3-aminothieno [2,3-b ] pyridine derivative and preparation method and application thereof | 四川大学 | 2017-07-07 | — | — | CN | disclosed |
| WO-2015110999-A1 | EZH2 INHIBITORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-07-30 | — | — | WO | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| EP-0337944-B1 | UREAS | CIBA-GEIGY AG (CH) | 1993-07-28 | — | — | EP | disclosed |
| US-4973690-A | PYRIMIDIN-2-YL UREAS, HERBICICES, PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1990-11-27 | — | — | US | disclosed |
| EP-0337944-A1 | Ureas | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | MCL1 2007/4885MAPK1 650/4885CA1 4855/4885 |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | MCL1 4760/4885MAPK1 3592/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.